论文部分内容阅读
目的：比较文拉法辛缓释剂和阿普唑仑治疗广泛性焦虑障碍的疗效。方法选取2013年2—7月在广元市精神卫生中心就诊的符合CCMD-3中广泛性焦虑障碍诊断标准的患者67例，随机分为研究组34例和对照组33例。研究组口服文拉法辛缓释剂治疗，对照组口服阿普唑仑治疗，疗程为4周。临床疗效判定依据汉密尔顿焦虑量表（ HAMA）减分率，不良反应采用不良反应量表（ TESS）评定。结果两组有效率比较，差异无统计学意义（ P﹥0.05）。治疗前两组HAMA评分比较，差异无统计学意义（ P﹥0.05）。第2周时研究组HAMA评分、精神性焦虑评分、躯体性焦虑评分低于对照组，差异有统计学意义（ P﹤0.05）。在第4周时研究组HAMA评分、精神性焦虑评分低于对照组，差异有统计学意义（ P﹤0.05）。结论文拉法辛缓释剂治疗广泛性焦虑症的短期效果优于阿普唑仑，不良反应两者无差异。“,”Objective To comPare the efficacy of extended venlafaxine and alPrazolam in the treatment of generalized anxiety disorder. Methods In Guangyuan Mental Health Center from February to July in 2013,a total of 67 Patients conformed to the generalized anxiety disorder CCMD-3 diagnostic criteria were selected and randomly divided into research grouP(34 ca-ses)and control grouP(33 cases). The Patients in research grouP were treated with extended venlafaxine,Patients in control grouP were treated with alPrazolam,for 4 weeks. Clinical efficacy and adverse reactions were assessed resPectively with Hamilton Anxiety Scale( HAMA ) reduced rate and Adverse Reactions Scale ( TESS ). Results The effective rate between the two grouPs showed no significant differences(P﹥0. 05). Before the treatment,the HAMA scores between the two grouPs showed no significant differences(P﹥0. 05). At the 2nd week,the HAMA scores,mental anxiety scores,somatic anxiety scores of research grouP were lower than those of control grouP,the differences were statistically significant(P ﹤0. 05). At the 4th week,the HAMD scores and mental anxiety scores were lower than those of control grouP,the differences were statistically sig-nificant( P﹤0. 05 ). Conclusion In short-term extended venlafaxine has better effect than alPrazolam in the treatment of generalized anxiety disorder,there was no difference in adverse reactions between the two drugs.